HEATHER DONIELLE JONES

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry ROSWELL, GA NPI 1689710790

General Payments — all program years on this page

$3,578.47

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 172
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $537.37 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $537.3717

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Otsuka America Pharmaceutical, Inc. $171.835
Neurocrine BioSciences, Inc. $134.395
ITI, Inc. $115.931
Teva Pharmaceuticals USA, Inc. $64.813
ABBVIE INC. $33.032
Indivior Inc. $17.381

By program year

Program yearAmountRecords
2018 $532.7419
2019 $539.8230
2020 $127.788
2021 $143.6913
2022 $390.5123
2023 $1,306.5662
2024 $537.3717

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1104007418 ABBVIE INC. $18.26 02/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104007420 ABBVIE INC. $14.77 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118916817 Otsuka America Pharmaceutical, Inc. $20.22 01/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118916819 Otsuka America Pharmaceutical, Inc. $10.93 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118916821 Otsuka America Pharmaceutical, Inc. $7.46 03/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118916823 Otsuka America Pharmaceutical, Inc. $124.98 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118916825 Otsuka America Pharmaceutical, Inc. $8.24 08/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1143251857 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $115.93 06/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144530776 Indivior Inc. $17.38 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150818984 Neurocrine Biosciences, Inc. $34.97 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150829768 Neurocrine Biosciences, Inc. $28.36 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150838206 Neurocrine Biosciences, Inc. $25.62 08/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150845177 Neurocrine Biosciences, Inc. $23.41 12/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150851106 Neurocrine Biosciences, Inc. $22.03 09/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151652132 Teva Pharmaceuticals USA, Inc. $33.11 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151652216 Teva Pharmaceuticals USA, Inc. $18.08 04/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151652256 Teva Pharmaceuticals USA, Inc. $13.62 07/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.